![Jump to content [Access key 'm']](/siteware/cleardot.gif){kind=small}
Oncology Programs
Cyclacel Pharmaceuticals, Inc. has built a deep pipeline of small molecule drug candidates, principally through internal discovery efforts, that target the cell cycle to treat human cancers and other serious disorders. Cyclacel’s pipeline currently includes three clinical-stage compounds, sapacitabine (CYC682), seliciclib (CYC202) and CYC116; a large portfolio of development candidates; and a productive drug discovery engine.
Cyclacel’s internal efforts have been focused on developing drugs for oncology indications. The company partners with other top-tier biotechnology and pharmaceutical companies to develop drugs for non-oncology indications.
Targeted Drug Pipeline
| Oncology Programs | CYC | Indication | Stage | Rights |
|---|---|---|---|---|
| Sapacitabine | 682 | CTCL, AML* | Phase 2 | Cyclacel/Sankyo |
| Seliciclib | 202 | NSCLC, NPC* | Phase 2 | Cyclacel |
| Aurora Kinase & VEGFR2 inhibitor | 116 | Cancer | IND-submitted | Cyclacel |
| 2G* CDK inhibitors | 400 | Cancer | Preclinical | Cyclacel |
| Clotrimazole analogs | 381 | Cancer | Preclinical | Cyclacel |
| Polo kinase inhibitors | 800 | Cancer | Preclinical | Cyclacel |
| Hdm2 inhibitors | 700 | Cancer | Preclinical | Cyclacel |
| CBG inhibitors* | 103 | Cancer | Preclinical | Cyclacel |
| Other Therapeutic Areas | ||||
| Nephrology* | TBD* | Inflammation | Preclinical | Cyclacel |
| GSK-3 inhibitors* | TBD* | T2 Diabetes | Preclinical | Cyclacel |
| HIV Cell Cycle inhibitors | TBD* | HIV | Preclinical | Cyclacel |
NB: CTCL= cutaneous T-Cell Lymphoma, AML = elderly acute myeloid leukaemia, NSCLC = non-small cell lung cancer, NPC = nasopharyngeal cancer, T2G = 2nd generation. CDK = cyclin dependent kinase. CBG = cyclin binding groove. GSK-3 = glycogen synthase kinase - 3.
Nephrology = inflammatory kidney disease. TBD = to be disclosed
